About the Project
This PhD project will focus on characterizing genomic mutations that cause synthetic lethality by enhancing the responses of ovarian cancer cells to chemotherapy. The project involves genetic screens, function and pathway analyses as well as anti-cancer drug assays. This research will reveal critical mechanisms determining chemotherapy responses in ovarian cancer, with potential to have a major translational impact on patient survival.
This is an exciting opportunity to identify new approach to treat cancer. We are looking for candidates who are highly motivated, fluent in English with wet lab experience in biological or biomedical science. Students will become proficient in cell culture, tumor biology, a wide range of cellular and molecular techniques, and omics analyses.
Dr. Lydia Cheung has a major interest in genomic characterization and the associated signaling of cancer, through which we will understand the biology of treatment response and drug resistance. We have identified a number of genomic alterations that may inform therapeutic responses.
Further details about our work are available at
Faculty information, funding opportunities and application deadlines: https://www.findaphd.com/phds/program/biomedical-research-hku-li-ka-shing-faculty-of-medicine/?i586p4119
(1) Li X et al. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. 2019. Nature Communications 10 (1), 716
(2) Cheung LW et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. 2014 Cancer Cell 26 (4), 479-494
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.